Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix Immunogenicity and Safety Study in Healthy Females
NCT00345878Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2006
- Primary completion
- Dec 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection, sponsored by GSK. Started Sep 2006; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00345878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00345878.